Farms.com Home   Ag Industry News

FDA Clamps Down on ‘Gluten-Free’ Labels

By Amanda Brodhagen, Farms.com

There are now stricter regulations governing the use of “gluten-free” claims placed on packaged food in the United States. Earlier this week, the Food and Drug Administration (FDA) determined that gluten-free can only be used for food products containing less than 20 parts per million of gluten.

The FDA issued the change in 2013, but the rule wasn’t enforced until a year later. Prior to August 5, 2014, there were no standards restricting the use of gluten-free labels on food products sold in the U.S.  The FDA said that the term will still be voluntary, but that companies must market foods as gluten-free “in a truthful and not misleading manner.”

Gluten greatly affects people with celiac disease, a condition which is triggered by consuming foods that contain wheat, barley, rye and oats. According to the FDA, an estimated 3 million Americans suffer from celiac disease, while some other people are sensitive to gluten or avoid it for personal reasons.  Celiac disease is classified as an autoimmune disorder of the small intestine. Symptoms include pain and discomfort in the digestive tract, along with a host of other issues, including anaemia and fatigue. The disease occurs in genetically predisposed people of all ages.

The legal definition of gluten-free, offers protection to American consumers from false or misguided marketing claims. Going forward, the FDA will be tasked to monitor gluten-free products to ensure that they have not been accidently cross-contaminated with gluten-containing products. For example oats are usually gluten-free, but are commonly grown with wheat and barley, which raises complications.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.